Shamburg News · 8-K filed Oct 30, 2026, 6:25 PM EDT

Aptevo Therapeutics Files Prospectus Supplement for Up to $2.3 Million At-the-Market Share Offering

APVO · Aptevo Therapeutics Inc.

  • Financing
  • Other
  • Materiality: low

On October 30, 2026, Aptevo Therapeutics Inc. filed a prospectus supplement under its effective Form S-3 registration statement covering up to $2,309,834 of common stock under its At The Market Offering Agreement with Roth Capital Partners, LLC. As of the supplement date, the company had sold 303,157 shares under the sales agreement and prior prospectus for aggregate gross proceeds of $11.8 million. Paul Hastings LLP issued a legal opinion on the shares, filed as Exhibit 5.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-442031.

Written from the filing by Shamburg Markets. Figures are as reported by the company.